MicroRNA-based linkage between aging and cancer: From epigenetics view point

Cell Journal

Volumn 18, Issue 2, 2016, Pages 117-126

  Saeidimehr, Saeid ^a   Ebrahimi, Ammar ^b   Saki, Najmaldin ^c   Goodarzi, Parisa ^d   Rahim, Fakher ^c  

^a Naft Hospital   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ageing; Disability; Genomics; Longevity; MicroRNAs

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA;

AGING; BIOGENESIS; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL AGING; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; HISTONE MODIFICATION; HUMAN; NEOPLASM; NONHUMAN; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION;

EID: 84976873337     PISSN: 22285806     EISSN: 22285814     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Dillin A, Gottschling DE, Nyström T. The good and the bad of being connected: the integrons of aging. Curr Opin Cell Biol. 2014; 26: 107-112.
2. Mohile SG, Magnuson A. Comprehensive geriatric assessment in oncology. Interdiscip Top Gerontol. 2013; 38: 85-103.
3. Ko YC, Fang WH, Lin TC, Hou HA, Chen CY, Tien HF, et al. MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia. Leuk Res. 2014; 38(5): 625-631.
4. Repetto L, Venturino A, Fratino L, Serraino D, Troisi G, Gianni W, et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer. 2003; 39(7): 870-880.
5. Salmanidis M, Pillman K, Goodall G, Bracken C. Direct transcriptional regulation by nuclear microRNAs. Int J Biochem Cell Biol. 2014; 54: 304-311.
6. Chitnis NS, Pytel D, Bobrovnikova-Marjon E, Pant D, Zheng H, Maas NL, et al. miR-211 is a prosurvival microRNA that regulates chop expression in a PERK-dependent manner. Mol Cell. 2012; 48(3): 353-364.
7. Saki N, Abroun S, Soleimani M, Hajizamani S, Shahjahani M, Kast RE, et al. Involvement of microRNA in T-cell differentiation and malignancy. Int J Hematol Oncol Stem Cell Res. 2015; 9(1): 33-49.
8. Wang F, Sun GP, Zou YF, Hao JQ, Zhong F, Ren WJ. MicroRNAs as promising biomarkers for gastric cancer. Cancer Biomark. 2012; 11(6): 259-267.
9. Yin Y, Li J, Chen S, Zhou T, Si J. MicroRNAs as diagnostic biomarkers in gastric cancer. Int J Mol Sci. 2012; 13(10): 12544-12555.
10. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7): 522-531.
11. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003; 67(4): 657-685.
12. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008; 30(4): 460-471.
13. Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010; 11(7): 537-561.
14. Kim VN, Nam JW. Genomics of microRNA. Trends Genet. 2006; 22(3): 165-173.
15. MacRae IJ, Doudna JA. Ribonuclease revisited: structural insights into ribonuclease III family enzymes. Curr Opin Struct Biol. 2007; 17(1): 138-145.
16. Lim AK, Tao L, Kai T. piRNAs mediate posttranscriptional retroelement silencing and localization to pi-bodies in the Drosophila germline. J Cell Biol. 2009; 186(3): 333-342.
17. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4): 642-655.
18. Shabalina SA, Koonin EV. Origins and evolution of eukaryotic RNA interference. Trends Ecol EVol. 2008; 23(10): 578-587.
19. Mattick JS, Makunin IV. Small regulatory RNAs in mammals. Hum Mol Genet. 2005; 14 Spec No 1: R121-132.
20. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006; 20(5): 515-524.
21. Alqurashi N, Hashimi SM, Wei MQ. Chemical inhibitors and microRNAs (miRNA) targeting the mammalian target of rapamycin (mTOR) pathway: potential for novel anticancer therapeutics. Int J Mol Sci. 2013; 14(2): 3874-3900.
22. Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012; 13(2): 1886-1918.
23. Hands SL, Proud CG, Wyttenbach A. mTOR's role in ageing: protein synthesis or autophagy? Aging (Albany NY). 2009; 1(7): 586-597.
24. Khapre RV, Kondratova AA, Patel S, Dubrovsky Y, Wrobel M, Antoch MP, et al. BMAL1-dependent regulation of the mTOR signaling pathway delays aging. Aging (Albany NY). 2014; 6(1): 48-57.
25. Jin Y, Tymen SD, Chen D, Fang ZJ, Zhao Y, Dragas D, et al. MicroRNA-99 family targets AKT/mTOR signaling pathway in dermal wound healing. PLoS One. 2013; 8(5): e64434.
26. Grundmann S, Hans FP, Kinniry S, Heinke J, Helbing T, Bluhm F, et al. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation 2011; 123(9): 999-1009.
27. Zheng Y, Li S, Ding Y, Wang Q, Luo H, Shi Q, et al. The role of miR-18a in gastric cancer angiogenesis. Hepatogastroenterology 2013; 60(127): 1809-1813.
28. Wan G, Xie W, Liu Z, Xu W, Lao Y, Huang N, et al. Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy 2014; 10(1): 70-79.
29. Shen C, Houghton PJ. The mTOR pathway negatively controls ATM by up-regulating miRNAs. Proc Natl Acad Sci USA. 2013; 110(29): 11869-11874.
30. Zhong M, Bian Z, Wu Z. miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma. Cell Physiol Biochem. 2013; 31(23): 209-218.
31. Wang Y, Liu J, Liu C, Naji A, Stoffers DA. MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic β-cells. Diabetes. 2013; 62(3): 887-895.
32. Li G, Cai M, Fu D, Chen K, Sun M, Cai Z, et al. Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma. Cell Physiol Biochem. 2012; 30(6): 1481-1490.
33. Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X, et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer. 2012; 12: 546.
34. Iwaya T, Yokobori T, Nishida N, Kogo R, Sudo T, Tanaka F, et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis. 2012; 33(12): 2391-2397.
35. Gebeshuber CA, Martinez J. miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene. 2013; 32(27): 3306-3310.
36. Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, et al. MiR506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 2014; 233(3): 308-318.
37. Mazan-Mamczarz K, Zhao XF, Dai B, Steinhardt JJ, Peroutka RJ, Berk KL, et al. Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development. PLoS Genet. 2014; 10(1): e1004105.
38. Bozdag S, Li A, Riddick G, Kotliarov Y, Baysan M, Iwamoto FM, et al. Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS One. 2013; 8(4): e62982.
39. Huidobro C, Fernandez AF, Fraga MF. Aging epigenetics: causes and consequences. Mol Aspects Med. 2013; 34(4): 765-781.
40. Hu W, Wang T, Xu J, Li H. MicroRNA mediates DNA methylation of target genes. Biochem Biophys Res Commun. 2014; 444(4): 676-681.
41. Zhang Z, Zhang MQ. Histone modification profles are predictive for tissue/cell-type specific expression of both protein-coding and microRNA genes. BMC Bioinformatics. 2011; 12: 155.
42. Wakabayashi T, Hidaka R, Fujimaki S, Asashima M, Kuwabara T. MicroRNAs and epigenetics in adult neurogenesis. Adv Genet. 2014; 86: 27-44.
43. Ng HY, Wan TS, So CC, Chim CS. Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia. J Clin Pathol. 2014; 67(7): 626-631.
44. Xie K, Liu J, Chen J, Dong J, Ma H, Liu Y, et al. Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. Gene. 2014; 543(1): 101-107.
45. Huang YW, Kuo CT, Chen JH, Goodfellow PJ, Huang TH, Rader JS, et al. Hypermethylation of miR-203 in endometrial carcinomas. Gynecol Oncol. 2014; 133(2): 340-345.
46. Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA, Hesselink AT, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 2014; 15(3): 315-322.
47. Li N, Zhang F, Li S, Zhou S. Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell. Biochem Biophys Res Commun. 2014; 444(4): 611-616.
48. Ben Gacem R, Ben Abdelkrim O, Ziadi S, Ben Dhiab M, Trimeche M. Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease. Tumour Biol. 2014; 35(5): 4047-4056.
49. Wang LQ, Kwong YL, Kho CS, Wong KF, Wong KY, Ferracin M, et al. Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia-implications on constitutive activation of NFκB pathway. Mol Cancer. 2013; 12: 173.
50. Yamada N, Noguchi S, Kumazaki M, Shinohara H, Miki K, Naoe T, et al. Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukaemia jurkat cells by modulating expression of fas-associated protein with death domain (FADD). Biochim Biophys Acta. 2014; 1843(3): 590-602.
51. Nadal E, Chen G, Gallegos M, Lin L, Ferrer-Torres D, Truini A, et al. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2013; 19(24): 6842-6852.
52. Xing TJ, Xu HT, Yu WQ, Jiang DF. Methylation regulation of liver-specific microRNA-122 expression and its effects on the proliferation and apoptosis of hepatocellular carcinoma cells. Genet Mol Res. 2013; 12(3): 3588-3597.
53. Zhang J, Zhou Y, Wu YJ, Li MJ, Wang RJ, Huang SQ, et al. Hyper-methylated miR-203 dysregulates ABL1 and contributes to the nickel-induced tumorigenesis. Toxicol Lett. 2013; 223(1): 42-51.
54. Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep. 2013; 30(4): 1976-1984.
55. Azizidoost S, Bavarsad MS, Bavarsad MS, Shahrabi S, Jaseb K, Rahim F, et al. The role of notch signaling in bone marrow niche. Hematology. 2015; 20(2): 93-103.
56. Hong CC, Chen PS, Chiou J, Chiu CF, Yang CY, Hsiao M, et al. miR-326 maturation is crucial for VEGF-C-driven cortactin expression and esophageal cancer progression. Cancer Res. 2014; 74(21): 6280-6290.
57. Luo J, Wu J, Li Z, Qin H, Wang B, Wong TS, et al. miR-375 Suppresses IGF1R expression and contributes to inhibition of cell progression in laryngeal squamous cell carcinoma. Biomed Res Int. 2014; 2014: 374598.
58. Wang W, Ren F, Wu Q, Jiang D, Li H, Shi H. MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer. Oncol Rep. 2014; 32(5): 2127-2133.
59. Saki N, Abroun S, Soleimani M, Hajizamani S, Shahjahani M, Kast RE, et al. Involvement of microRNA in T-cell differentiation and malignancy. Int J Hematol Oncol Stem Cell Res. 2015; 9(1): 33-49.
60. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11): 857-866.
61. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007; 67(16): 7713-7722.
62. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3): 189-198.
63. Alemar B, Gregorio C, Ashton-Prolla P. miRNAs as diagnostic and prognostic biomarkers in pancreatic ductal adenocarcinoma and its precursor lesions: a review. Biomark Insights. 2015; 10: 113-124.
64. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012; 6(6): 590-610.
65. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007; 302(1): 1-12.
66. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006; 25(46): 6188-6196.
67. Lehmann U, Hasemeier B, Römermann D, Müller M, Länger F, Kreipe H. [Epigenetic inactivation of microRNA genes in mammary carcinoma]. Verh Dtsch Ges Pathol. 2007; 91: 214-220.
68. Jin H, Liang Y, Wang X, Zhu J, Sun R, Chen P, et al. Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. Med Oncol. 2014; 31(10): 221.
69. Izzotti A. Molecular medicine and the development of cancer chemopreventive agents. Ann NY Acad Sci. 2012; 1259: 26-32.
70. Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, et al. High let-7a microRNA levels in KRASmutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist. 2012; 17(6): 823-829.
71. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5): 635-647.
72. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA. 2008; 105(10): 3903-3908.
73. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer. 2007; 7(11): 819-822.
74. Liang Z, Ahn J, Guo D, Votaw JR, Shim H. MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res. 2013; 30(4): 1008-1016.
75. Itahana Y, Han R, Barbier S, Lei Z, Rozen S, Itahana K. The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. Oncogene. 2015; 34(14): 1799-1810.